UnknownNCT03949192
Efficacy of Kangliuwan for Recurrent Grade IV Glioma
Studying Glial tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Xuanwu Hospital, Beijing
- Principal Investigator
- Qingtang Lin, M.D., Ph.D.Xuanwu Hospital, Beijing
- Enrollment
- 20 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2019 – 2021
Study locations (1)
- Xuanwu Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03949192 on ClinicalTrials.govOther trials for Glial tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07210632Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)Eben Rosenthal
- RECRUITINGNCT07236840Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain TumorsTata Memorial Centre
- RECRUITINGNCT07240662Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse GliomaiOMEDICO AG
- RECRUITINGNCT07405372Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of GliomasDaping Hospital and the Research Institute of Surgery of the Third Military Medical University
- RECRUITINGPHASE2NCT07110246Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasUniversity of California, San Francisco
- RECRUITINGPHASE1NCT07223034A Study of 177Lu-PSMA-617 in People With GliomasMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGNCT07238322[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related ChangesTelix Pharmaceuticals (Innovations) Pty Limited
- RECRUITINGNANCT06397560PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies TrialBaptist Health South Florida